Caussy Cyrielle, Aubin Adrien, Loomba Rohit
Hôpital Lyon Sud, Département Endocrinologie, Diabète et Nutrition, Hospices Civils de Lyon, 69495, Pierre-Bénite, France.
Department of Medicine, NAFLD Research Center, University of California at San Diego, La Jolla, CA, USA.
Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are strongly associated. Both also associate with an increased risk of cardiovascular disease (CVD).
Several studies have provided evidence that NAFLD could be an independent CVD risk factor. Given the strong association between NAFLD and T2DM, assessing the independent CV effect of these two conditions remains challenging. However, patients with T2DM and NAFLD exhibit higher risk of CVD compared with T2DM without NAFLD suggesting a potential synergistic increase of CV risk in patients with both T2DM and NAFLD supported by several shared pathophysiological pathways. Several anti-diabetic therapies have shown beneficial effect on both NAFLD and CVD. Patients with T2DM and NAFLD should be considered at high risk of CVD and could benefit from more intensive CV prevention. Additional long-term follow-up is needed to demonstrate that the treatment of NAFLD effectively reduces the risk of CVD.
非酒精性脂肪性肝病（NAFLD）与2型糖尿病（T2DM）密切相关。两者还都与心血管疾病（CVD）风险增加有关。
多项研究提供了证据表明NAFLD可能是一个独立的CVD风险因素。鉴于NAFLD与T2DM之间的紧密关联，评估这两种情况的独立心血管效应仍然具有挑战性。然而，与无NAFLD的T2DM患者相比，T2DM合并NAFLD患者表现出更高的CVD风险，这表明在T2DM合并NAFLD患者中，心血管风险可能存在潜在的协同增加，这得到了几种共同病理生理途径的支持。几种抗糖尿病疗法已显示出对NAFLD和CVD均有益。T2DM合并NAFLD患者应被视为CVD高危人群，可能会从更强化的心血管预防中获益。需要更多长期随访来证明NAFLD的治疗能有效降低CVD风险。
